Drugs in ATC Class L01EX

Up to Top Level ATC Classes

Up to L - Antineoplastic and immunomodulating agents

Up to L01 - ANTINEOPLASTIC AGENTS

Up to L01E - PROTEIN KINASE INHIBITORS

Drugs in ATC Class: L01EX - Other protein kinase inhibitors

Tradename	Generic Name
SUNITINIB MALATE	sunitinib malate
SUTENT	sunitinib malate
NEXAVAR	sorafenib tosylate
SORAFENIB TOSYLATE	sorafenib tosylate
PAZOPANIB HYDROCHLORIDE	pazopanib hydrochloride
VOTRIENT	pazopanib hydrochloride
CAPRELSA	vandetanib

Last updated: June 12, 2026

rket dynamics and patent landscape for ATC Class L01EX: Other protein kinase inhibitors

ATC L01EX spans multiple small-molecule and kinase-targeting modalities with distinct revenue drivers and IP expiry patterns. The patent landscape is dominated by (1) primary composition-of-matter (CoM) patents for specific kinase inhibitors, (2) incremental patents for crystalline forms, polymorphs, salts, solvates, particle size and formulation, (3) method-of-use patents tied to line-of-therapy and biomarker-defined subpopulations, and (4) manufacturing-process patents.

A high-level view of market dynamics: revenue concentration in a limited set of top-selling L01EX agents raises the importance of “late-life” lifecycle patents (reformulation, line extensions, combination regimens) and creates a litigation-driven launch cadence for generics. Competitive pressure typically increases after primary CoM expiry, but exclusivity risk is more strongly determined by whether the Orange Book or equivalent trademark-regulatory listings show blocking formulation or method-of-use patents.

What patents protect ATC L01EX (other protein kinase inhibitors) and how are they structured?

L01EX is a taxonomy bucket rather than a single drug family. Patent protection therefore tracks drug-by-drug: each active ingredient has its own core CoM estate and a layered “evergreening” stack that can extend effective exclusivity beyond headline filing/expiry dates.

How are L01EX patent estates usually layered?

Typical IP stacks for kinase inhibitors across L01EX include:

• Composition of matter (CoM): compounds, analog series, and key substitutions.
• Stereochemistry and tautomer control: where relevant, separate claims may cover specific stereoisomers.
• Polymorphs, salts, hydrates, solvates: especially for drugs with solubility and stability constraints.
• Particle engineering: micronization, particle-size distribution, spray-dried dispersions.
• Formulations: tablets/capsules with defined excipient systems, film coatings, dissolution targets.
• Manufacturing process: crystallization conditions, solvent systems, yield and impurity control.
• Method of use: dosing regimens, combinations, and biomarker-defined indications (often aligned to FDA labels).

What patent types most often block generic or biosimilar-style substitution?

For small-molecule kinase inhibitors, the blocking patents are usually:

• Formulation and solid-state patents listed in the regulatory patent register (Orange Book in the US).
• Method-of-use patents tied to a labeled or supported indication and dosage.
• Combination regimen patents that can be used as a “block” even when the single agent has primary expiry.

Which jurisdictions shape the enforcement reality for L01EX agents?

• US: Orange Book listings and Paragraph IV litigation risk determine generic entry timing.
• EU: national SPCs and supplementary protection certificates often control practical expiry.
• UK: post-Brexit SPC status remains a critical axis.
• Japan and other markets: patent term adjustments, enforcement scope, and local registration practices influence launch.

When do ATC L01EX patent estates lose exclusivity and what is the effective “last day to launch” window?

There is no single expiry date for L01EX. Effective launch timing is a function of the specific active ingredient’s:

1. Primary CoM expiry (20 years from earliest non-provisional filing, subject to jurisdiction rules).
2. Patent term adjustment (US PTA) and patent term extensions.
3. Supplementary protection certificates (SPCs) and pediatric extensions.
4. Regulatory exclusivities (data exclusivity, market exclusivity, orphan exclusivity where applicable).
5. Whether blocking Orange Book patents remain valid for the relevant NDA strength/dosage form.
6. Whether a Paragraph IV settlement includes “180-day exclusivity” for the first filer and stipulated entry dates.

How to interpret “effective exclusivity” for L01EX?

• Headline CoM expiry often does not equal launch freedom.
• If solid-state or method-of-use patents remain listed and enforceable, generics face either continued injunction risk or forced launch carve-outs.
• Where settlements exist, the “entry date” can reflect court-driven economics rather than strictly scheduled expiry.

Typical timeline mechanics for L01EX generic entry

Common pattern after primary expiry:

• Orange Book listing review identifies blocking patents.
• Paragraph IV filing triggers automatic FDA stay (if applicable) and litigation windows.
• Settlement can fix a contractually protected entry date.
• Final court outcomes determine whether non-settling generics can launch earlier.

What generic entry risks exist for L01EX drugs after Paragraph IV filings?

L01EX generics typically face three risk layers:

• Legal risk: likelihood of invalidity or non-infringement arguments succeeding against formulation or method-of-use claims.
• Regulatory risk: whether the ANDA or 505(b)(2) product can align to a non-infringing strength/dosage form (or different solid-state form).
• Commercial risk: whether “design-around” leads to slower uptake due to cost, bioequivalence, or clinician preference.

What claims are most frequently attacked in L01EX Paragraph IV litigations?

• Obviousness based on prior kinase inhibitor disclosures.
• Lack of written description or enablement where early filings are narrow.
• Non-infringement via different polymorph/salt selection, process differences, or dosing schedules.

What evidence tends to be decisive in kinase inhibitor infringement?

• Solid-state characterization and manufacturing records (for polymorph/formulation claims).
• Labeling and trial evidence (for method-of-use claims).
• Claim construction around combination endpoints and biomarker language.

How many patents cover each L01EX active ingredient and which assignees control the estate?

The number of patents varies widely by molecule and lifecycle strategy: some L01EX inhibitors have a small core family with a limited number of granted patents, while others have multiple follow-on filings spanning solid-state, manufacturing, and multiple labeled indications.

Asset control typically sits with:

• Original NDA holder (often a large pharma or specialty oncology company).
• Spinouts or acquired biotechs if the compound originated as a development-stage asset.
• Academic or government institutions where early discovery was publicly funded (less common for later-life filings, more common for foundational methods).

What is the Orange Book status of ATC L01EX kinase inhibitors and how many listed blocking patents are there?

Orange Book status is molecule-specific and drives actionable generic risk. For L01EX, the practical question is not “how many patents exist,” but “how many are listed against the approved dosage forms and strengths.”

How Orange Book listings typically map to claim scope

• Formulation patents often list against specific NDCs.
• Method-of-use patents list against the NDA as an “use” patent tied to the label.
• Some companies list multiple patents that cover overlapping claim scopes for the same dosage form, increasing settlement leverage.

Why this matters for launch forecasting

Two L01EX agents with similar CoM expiry can have different launch dates because:

• blocking patents remain listed for one molecule and are absent for the other,
• one has a settled Paragraph IV runway while the other litigates through final judgments,
• one has an active SPC regime in addition to US filings (EU/UK).

Which ATC L01EX drugs have the strongest patent estates (and why do they keep generics out)?

Strength is usually determined by:

• Density of granted claims around core and lifecycle areas.
• Breadth of claim language in CoM and solid-state patents.
• Whether method-of-use claims track label wording (making non-infringement harder).
• History of enforcement outcomes and settlement patterns that deter Paragraph IV challengers.
• Whether “design-around” remains commercially viable (some polymorph variants are not equivalent in stability, bioavailability, or manufacturability).

Practical indicators of estate strength

• Multiple generations of granted patents still within enforceable term.
• High proportion of patents that are listed and therefore enforceable in ANDA litigation context.
• Prior settlements establishing entry dates that anchor the market.

What formulation patents protect L01EX kinase inhibitors and how do they affect ANDA design-around?

Formulation and solid-state protection is a major driver for L01EX lifecycle control because many kinase inhibitors have:

• solubility-limited dissolution characteristics,
• polymorphic behavior that can shift exposure and stability,
• tight impurity profiles requiring controlled crystallization processes.

Common protected formulation features in L01EX

• Salt form selection (e.g., hydrochloride, fumarate, maleate where applicable).
• Polymorphs/solvates with defined XRPD peaks and DSC profiles.
• Amorphous solid dispersions with defined polymer ratios.
• Particle size and milling conditions impacting bioavailability.

What generic strategies are used

• Different salt/polymorph selection where claim scope permits.
• Process and crystallization condition changes to obtain non-claimed forms.
• Formulation re-engineering that still achieves FDA bioequivalence.

Which method-of-use patents drive exclusivity for L01EX oncology regimens?

Method-of-use patents dominate enforcement when they align to labeled indications for oncology kinase inhibitors:

• line-of-therapy specificity (first-line versus post-progression),
• biomarker constraints (mutation status, expression status),
• combination regimens (with checkpoint inhibitors, chemotherapy, or other targeted agents),
• dosing schedule specifics tied to clinical trial outcomes.

How method-of-use claims impact generic availability

• A generic of the active ingredient may still be prevented from marketing “for the patented use.”
• Carve-outs are possible but depend on label changes and whether FDA can approve them without undermining therapeutic equivalence.

What patent litigation affects L01EX drugs and what are the usual outcomes?

L01EX litigation follows a common cadence: complaint after Paragraph IV ANDA filing; Markman claim construction; summary judgment on infringement/invalidity; and appeal.

Typical litigation outcomes that shape market entry

• Settlement with defined entry date and often “carve-out” label restrictions.
• Final court rulings sustaining key patents, delaying launch.
• Partial invalidation or non-infringement that narrows claim scope, enabling “design-around” products.

Where settlements are most common

• When formulation or method-of-use claims are fact-intensive and require product-specific comparison.
• When both parties see risk of expensive trials and appeals.

How does FDA regulatory status intersect with patent life for L01EX?

FDA pathways influence timing but do not erase patent barriers. For L01EX small molecules, ANDA and 505(b)(2) pathways interact with patent listings and exclusivities.

Key regulatory status items that affect exclusivity

• NDA approvals and label indications defining what method-of-use patents may cover.
• 5-year and 3-year exclusivities where applicable to data and market.
• Orphan drug designations when relevant (can add statutory market exclusivity).
• Change approvals (label expansions, new combinations) that can trigger new patent listings.

How do L01EX drugs compare in competitive landscape and revenue exposure?

L01EX competitive dynamics are driven by:

• how many labeled indications expand the addressable market,
• whether combinations win standard-of-care positions,
• whether adverse events profiles support sustained use,
• the time gap between first and later-lifecycle patent expiry.

Revenue exposure mapping logic

For pipeline and licensing decisions, the revenue exposure of each L01EX agent depends on:

• share of prescriptions tied to indications under active method-of-use patents,
• dependency on specific dosage forms that are subject to formulation patents,
• expected generic uptake rate after approval of first ANDA launch.

What generic launch scenarios exist for L01EX when patents expire?

Common scenarios after the blocking patent wall falls:

1. Full launch: generic reaches the same label breadth and dosage forms.
2. Label carve-out launch: generic launches with narrowed indications to avoid method-of-use infringement.
3. Strength or dosage-form limitation: generic launches only for non-implicated strengths/NDCs.
4. Delayed launch due to ongoing appeals: even after district court decisions, appeals can postpone market entry.
5. Settlement “stair-step”: multiple entrants launch at different dates tied to a settlement ladder.

Key takeaways

• ATC L01EX market exclusivity is not one timeline; it is molecule-by-molecule, driven by Orange Book-listed blocking patents, SPCs, and settlements.
• Patent estates for kinase inhibitors commonly concentrate strength in formulation/solid-state and method-of-use layers rather than the original CoM alone.
• Generic entry risk is highest when multiple granted patents are listed for the same NDC/indication and when method-of-use language tracks the FDA label.
• Effective exclusivity windows usually extend beyond headline CoM expiry through incremental patents, regulatory exclusivities, and Paragraph IV litigation dynamics.

FAQs

1. Which L01EX patents are typically listed in the Orange Book against specific NDCs versus only “use” patents?
2. How do polymorph and salt selection patents constrain ANDA design-around for kinase inhibitors in L01EX?
3. When settlements occur in Paragraph IV cases, what factors most often determine the stipulated generic entry date?
4. Do label expansions for L01EX drugs create new patent listings that change the generic launch forecast?
5. How does SPC availability in the EU/UK alter the effective expiry window compared with US-only CoM timelines for L01EX inhibitors?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA.
2. FDA. Approved Drug Products (Drugs@FDA) Database. US FDA.
3. FDA. Drug Development and Approval Process: Pathways. US FDA.
4. European Medicines Agency (EMA). Supplementary Protection Certificates (SPC) Overview. EMA.